Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Working tool

Incretin dose equivalence

Illustrative equivalence anchored on placebo-subtracted weight change at the highest dose evaluated in each pivotal programme.

§1Calculator

Incretin dose equivalence — illustrative
Illustrative equivalent dose
Implied placebo-subtracted weight change
Ceiling of the comparator programme

§2The anchor and its limits

The anchor is the placebo-subtracted percentage weight change reported at the highest dose evaluated in each compound's pivotal programme. Two compounds are treated as equivalent at doses producing the same anchored effect.

The anchor models nothing else. It does not model titration schedule, tolerability, glycaemic effect, cardiovascular effect, duration of exposure, or the population in which the anchoring estimate was obtained. Two of the compounds in the list have only phase 2 evidence, and a phase 2 estimate in a selected population is systematically larger than the confirmatory estimate that follows it.

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.